A prospective single arm, open-label, international, multicenter study to evaluate the safety, efficacy and pharmacokinetics of Atazanavir (ATV) powder boosted with Ritonavir (RTV) liquid with an optimized NRTI background therapy, in HIV infected pediatric patients greater than or equal to 3 months to less than 6 years; pediatric Atazanavir international clinical evaluation: The PRINCE I study

Project no.: HIV-NAT 143 (PRINCE 1)

This study will evaluate the pharmacokinetic and efficacy data of atazanavir/r in HIV-infected children.